Clinical Trials Logo

Filter by:
NCT ID: NCT03357692 Withdrawn - Clinical trials for Bone Atrophy, Alveolar

All-on-Four Implants With Ultrasonic

Nobelsinus
Start date: October 31, 2017
Phase: N/A
Study type: Interventional

The objective of this observational study is the radiographic evaluation of marginal bone remodeling after surgical implant insertion in an immediate loading all-on-four technique with trans-sinusal titanium implants, correlating the gingival thickness and the height of the implant prosthetic stump with the proportion of the abovementioned marginal bone remodeling.

NCT ID: NCT03349346 Withdrawn - Clinical trials for Diffuse Large B-Cell Lymphoma

Idelalisib With Rituximab, Ifosfamide, Carboplatin, Etoposide (RICE) in Children and Adolescents

Start date: June 2019
Phase: Phase 1
Study type: Interventional

The primary objectives of this study are to evaluate safety, tolerability, pharmacokinetics (PK) and preliminary efficacy of idelalisib; and to establish recommended phase 2 doses (RP2D) of idelalisib in combination with rituximab, ifosfamide, carboplatin, etoposide (RICE) in children and adolescents with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) or mediastinal B-cell lymphoma (MBCL)

NCT ID: NCT03340103 Withdrawn - Clinical trials for Antioxidant Role of the Lutein in Preterm Newborn

Early Administration of the Lutein/Zeaxanthin in Premature Newborns

Start date: October 11, 2018
Phase: N/A
Study type: Interventional

Premature birth is the most common cause of mortality, morbidity and disability. Premature infants have a higher risk of developing damage in the eyes (retinopathy of prematurity ROP), in the central nervous system (intraventricular hemorrhage IVH), in the lungs (bronchial pulmonary dysplasia BPD), in the gut (NEC) and infections. Oxidative stress has been implicated in various capacities, in the etiology of these conditions. Lutein and Zeaxanthin are powerful anti-oxidants and commonly assimilated with different foods. Lutein and Zeaxanthin are present at level of umbilical cord, in the breast milk (particularly in colostrum) and pass the placental barrier. Concerning supplementations, the lutein presents, for its specific characteristics, a high bioavailability after oral administration. In the last few years, there have been more and more studies which have shown that lutein could constitute a valid and important preventive and protective factor against certain diseases related to oxidative stress. The preparations of lutein and zeaxanthin have never pointed out in the human being (included in the term newborn) adverse or toxic effects. This spontaneous / non-commercial pilot study involves the administration of a dietary supplement containing lutein / zeaxanthin, because the healthcare structures need to identify a natural antioxidant product that can reduce the incidence of serious diseases related to oxidative stress in the perinatal period. This study aims to evaluate if the administration of lutein in watery solution will reduce the rate of free radicals in preterm infants.

NCT ID: NCT03282292 Withdrawn - Clinical trials for Congenital Heart Disease

Central Venous Catheter Insertion Site and Colonization in Pediatric Cardiac Surgery

PRECiSE
Start date: September 12, 2017
Phase: N/A
Study type: Interventional

Randomized controlled trial comparing femoral vs internal jugular insertion site of central venous catheters (CVC) in newborns and infants undergoing cardiac surgery. The experimental hypothesis is that the jugular insertion site is superior to the femoral in terms of catheter colonization.

NCT ID: NCT03231527 Withdrawn - Clinical trials for Coronary Artery Disease

Outcomes of Total Arterial Coronary Artery Bypass Grafting

MOZART
Start date: February 1, 2017
Phase:
Study type: Observational

"real-life" retrospective multicentric database for the analysis of the long term outcomes of total arterial CABG in comparison to saphenous vein based CABG

NCT ID: NCT03226236 Withdrawn - Clinical trials for Carcinoma, Renal Cell

Vaccination With Dendritic Cells Pulsed With Autologous Tumor Homogenate in Combination With HD-IL2 and Immunomodulating Radiotherapy in Metastatic RCC

RENALVax-2
Start date: March 2016
Phase: Phase 2
Study type: Interventional

Single center, open-label Proof of Principle phase II trial to assess objective response (ORR). Three daily doses boost radiotherapy (XRT) at 6-12 Gy to at least 1, and up to a maximum of 5, metastatic fields, will be administrated on days -4 -3 -2 or -3 -2 -1 before the first and the third cycle of vaccine+IL-2. The first day of administration of vaccine is day +1 and of IL-2 is day +2. Treatment vaccine plus IL-2 (dose 18 MIU/m2/day in 500cc by continuous IV infusion for 72 hours) will be administered every 3 weeks up to 6 cycles. Total duration of the trial: 36 months - Enrolment period: 24 months - Treatment: maximum of 6 cycles (5 months) per patient - Follow-up every three months until patient died (follow-up until PD and only survival contacts and subsequent therapy for metastatic disease after PD).

NCT ID: NCT03192969 Withdrawn - Clinical trials for Giant Cell Arteritis

A Study to Evaluate Efficacy and Safety of Subcutaneous Abatacept With Steroid Treatment Compared to Steroid Treatment Alone in Adults With Giant Cell Arteritis (GCA)

Start date: July 15, 2017
Phase: Phase 3
Study type: Interventional

To investigate the safety and efficacy of abatacept with steroid treatment in comparison to steroid treatment alone in up to a 28 week taper of steroid treatment to sustain remission of Giant Cell Arteritis in adults.

NCT ID: NCT03070691 Withdrawn - Clinical trials for Basal Cell Carcinoma

Efficacy, Safety and Tolerability of Topically Applied LDE225 Cream (Hedgehog Pathway Inhibitor) in Adult Patients With Nevoid Basal Cell Carcinoma Syndrome (NBCCS)

Start date: n/a
Phase: Phase 2/Phase 3
Study type: Interventional

This 22 week study will assess the efficacy, safety, and tolerability of LDE225 versus vehicle when applied topically to basal cell carcinoma (BCC) in patients with NBCCS. Patients will treat multiple BCCs for up to 12 weeks. Treatment success is defined as complete clinical clearance and complete histological clearance in BCCs.

NCT ID: NCT02984033 Withdrawn - Quality of Life Clinical Trials

Quality of Life and Psycological Evaluation of Patients Affected by Head and Neck Cancer

Start date: November 2016
Phase:
Study type: Observational

The prospective trial is to describe the quality of life and psychological effects in patients with head and neck tumor receiving curative intent treatment

NCT ID: NCT02980198 Withdrawn - Dermatomyositis Clinical Trials

Study of IFN-K in Dermatomyositis

Start date: May 3, 2017
Phase: Phase 2
Study type: Interventional

This study is a Proof of Concept study aiming to evaluate the production of anti-IFNα antibodies (immune response) in adult subjects with dermatomyositis